Candel Therapeutics (CADL) Expected to Announce Earnings on Tuesday

Key Points

• Candel Therapeutics is set to announce its Q2 2025 earnings on August 12th, with analysts expecting a loss of ($0.17) per share for the quarter.
• After reporting better-than-expected earnings of $0.13 per share in May, Candel's stock has decreased by 1.2%, trading at $6.24.
• The company has received a series of upgrades from analysts, currently holding an average rating of "Buy" with a target price of $22.00.

Candel Therapeutics (NASDAQ:CADL - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results before the market opens on Tuesday, August 12th. Analysts expect Candel Therapeutics to post earnings of ($0.17) per share for the quarter.

Candel Therapeutics (NASDAQ:CADL - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of ($0.24) by $0.37. On average, analysts expect Candel Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Candel Therapeutics Stock Performance

Shares of NASDAQ:CADL traded up $0.18 on Friday, hitting $6.02. The company had a trading volume of 475,967 shares, compared to its average volume of 838,591. Candel Therapeutics has a 1-year low of $3.79 and a 1-year high of $14.60. The stock has a market cap of $301.60 million, a price-to-earnings ratio of -4.49 and a beta of -0.88. The stock has a 50 day moving average price of $5.78 and a 200 day moving average price of $6.38. The company has a current ratio of 4.64, a quick ratio of 4.64 and a debt-to-equity ratio of 0.01.

Analysts Set New Price Targets

Several equities analysts recently commented on CADL shares. Wall Street Zen upgraded shares of Candel Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Brookline Capital Management upgraded shares of Candel Therapeutics to a "strong-buy" rating in a research note on Wednesday, July 9th. Finally, HC Wainwright upgraded shares of Candel Therapeutics to a "buy" rating and set a $23.00 price target on the stock in a research note on Monday, June 30th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Candel Therapeutics currently has a consensus rating of "Buy" and an average target price of $22.00.

Institutional Investors Weigh In On Candel Therapeutics

Large investors have recently bought and sold shares of the company. Geode Capital Management LLC lifted its holdings in shares of Candel Therapeutics by 31.5% in the second quarter. Geode Capital Management LLC now owns 903,970 shares of the company's stock worth $4,575,000 after acquiring an additional 216,509 shares during the last quarter. Rhumbline Advisers raised its holdings in Candel Therapeutics by 26.8% in the 1st quarter. Rhumbline Advisers now owns 33,302 shares of the company's stock valued at $188,000 after buying an additional 7,030 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Candel Therapeutics by 37.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,748 shares of the company's stock worth $95,000 after purchasing an additional 4,583 shares during the last quarter. Finally, Invesco Ltd. bought a new position in Candel Therapeutics during the 1st quarter worth approximately $59,000. 13.93% of the stock is currently owned by institutional investors and hedge funds.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.